Key terms
About LVTX
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LVTX news
Apr 03
5:10am ET
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
Mar 24
9:27pm ET
Buy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financials
Mar 22
1:25pm ET
LAVA Therapeutics: A Strong Buy on Robust Financials and Promising Oncology Pipeline Advancements
Mar 21
7:57am ET
LAVA Therapeutics Announces Progress and Stability
Mar 21
6:18am ET
Strong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial Outlook
Mar 20
7:06am ET
Lava Therapeutics reports Q4 EPS (24c), consensus (12c)
Mar 05
7:37am ET
Lava Therapeutics announces clinical development milestone achieved by Pfizer
Mar 01
1:23am ET
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)
Feb 02
12:26am ET
Strong Buy Rating for LAVA Therapeutics Amid Strategic Partnerships and Promising Clinical Advancements
Jan 25
7:18am ET
Lava enters collaboration with Merk to evaluate LAVA-1207, KEYTRUDA
No recent press releases are available for LVTX
LVTX Financials
Key terms
Ad Feedback
LVTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LVTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
